GT Biopharma, Inc. (NASDAQ:GTBP) Sees Significant Decrease in Short Interest

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large drop in short interest in March. As of March 13th, there was short interest totaling 1,019,371 shares, a drop of 51.2% from the February 26th total of 2,089,377 shares. Based on an average daily volume of 729,020 shares, the short-interest ratio is presently 1.4 days. Currently, 3.3% of the shares of the stock are short sold.

GT Biopharma Stock Performance

Shares of GT Biopharma stock traded down $0.04 on Friday, hitting $0.41. The stock had a trading volume of 1,124,936 shares, compared to its average volume of 700,959. The stock has a 50 day moving average of $0.51 and a 200 day moving average of $0.65. The firm has a market capitalization of $12.90 million, a P/E ratio of -0.06 and a beta of 1.28. GT Biopharma has a twelve month low of $0.39 and a twelve month high of $3.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of GT Biopharma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new position in shares of GT Biopharma, Inc. (NASDAQ:GTBP) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).